Compare STRT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | FULC |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 285.4M |
| IPO Year | 1996 | 2019 |
| Metric | STRT | FULC |
|---|---|---|
| Price | $60.35 | $3.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 45.9K | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.17 | N/A |
| EPS | ★ 5.00 | N/A |
| Revenue | ★ $439,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $57.01 | $2.83 |
| 52 Week High | $93.00 | $15.74 |
| Indicator | STRT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 42.62 |
| Support Level | $57.01 | $3.62 |
| Resistance Level | $83.87 | $3.91 |
| Average True Range (ATR) | 1.74 | 0.06 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 18.55 | 24.14 |
Strattec Security Corp designs automotive access company that designs and delivers safe, secure, and engineered access solutions for the automotive and mobility markets. Built on generations of access and security engineering expertise, partner closely with OEMs to create differentiated, system level access experiences for end consumers. Its product portfolio spans the access journey from Permission, enabling secure vehicle entry through advanced mechanical and electronic systems; to Motion, delivering effortless, reliable powered access that enhances everyday usability; and through to Hold, providing precision engineered latching solutions.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.